论文部分内容阅读
异基因外周血造血干细胞移植(allo-HSCT)非清髓性造血移植主要通过降低剂量的预处理、免疫抑制剂运用及供体淋巴细胞输注,使受体与移植细胞之间双向免疫耐受,实现异体造血干细胞的有效植入,利用移植物抗肿瘤效应(GVT)达到清除肿瘤细胞的目的[1~2]。由于预处理方案相对较弱,并发
Allogeneic peripheral blood stem cell transplantation (allo-HSCT) non-myeloablative hematopoietic transplantation mainly by reducing the dose of pretreatment, the use of immunosuppressive agents and donor lymphocyte infusion, the two-way immune tolerance between the recipient and the transplanted cells , To achieve the effective implantation of allogeneic hematopoietic stem cells, the use of graft anti-tumor effect (GVT) to achieve the purpose of removing tumor cells [1 ~ 2]. As the pretreatment program is relatively weak, complicated